Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A7NZ
|
||||
| Former ID |
DIB011505
|
||||
| Drug Name |
CNTO-6785
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] | Phase 2 | [1] | ||
| Company |
Janssen research & development
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-17 | Target Info | [2] | ||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| Inflammatory bowel disease (IBD) | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Interleukin signaling pathway | ||||
| Pathway Interaction Database | IL27-mediated signaling events | ||||
| IL23-mediated signaling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| Allograft Rejection | |||||
| IL17 signaling pathway | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01909427) An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy. U.S. National Institutes of Health. | ||||
| REF 2 | Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2. doi: 10.1038/nrd4518. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.